about
Alzheimer's disease, oestrogen and mitochondria: an ambiguous relationshipConnecting the dots between tau dysfunction and neurodegenerationTau-targeted treatment strategies in Alzheimer's diseaseTau physiology and pathomechanisms in frontotemporal lobar degenerationDendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse modelsTau promotes neurodegeneration via DRP1 mislocalization in vivoFGF5 as a regulator of the hair growth cycle: evidence from targeted and spontaneous mutationsInhibition of the mitochondrial enzyme ABAD restores the amyloid-β-mediated deregulation of estradiolDelayed embryonic lethality in mice lacking protein phosphatase 2A catalytic subunit CalphaDistinct role of protein phosphatase 2A subunit Calpha in the regulation of E-cadherin and beta-catenin during developmentAnimal models for Alzheimer's disease and frontotemporal dementia: a perspectiveMice lacking phosphatase PP2A subunit PR61/B'delta (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3beta.Premature lethality, hyperactivity, and aberrant phosphorylation in transgenic mice expressing a constitutively active form of Fyn.Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's diseaseFunctional Genomics meets neurodegenerative disorders. Part II: application and data integration.Tau filament formation in transgenic mice expressing P301L tau.Functional Genomics meets neurodegenerative disorders Part I: transcriptomic and proteomic technology.Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils.Hyperphosphorylated tau causes reduced hippocampal CA1 excitability by relocating the axon initial segment.Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model.Neuronal microRNA deregulation in response to Alzheimer's disease amyloid-betaRegulation of age-related structural integrity in neurons by protein with tau-like repeats (PTL-1) is cell autonomous.PTL-1 regulates neuronal integrity and lifespan in C. elegans.Neuroproteomics as a promising tool in Parkinson's disease research.Convergence of amyloid-beta and tau pathologies on mitochondria in vivo.Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons.Altered proteostasis in aging and heat shock response in C. elegans revealed by analysis of the global and de novo synthesized proteomeScanning ultrasound removes amyloid-β and restores memory in an Alzheimer's disease mouse model.Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease modelsAbeta and human amylin share a common toxicity pathway via mitochondrial dysfunction.Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice.In vivo analysis of wild-type and FTDP-17 tau transgenic mice.Tau-mediated nuclear depletion and cytoplasmic accumulation of SFPQ in Alzheimer's and Pick's disease.Role for glyoxalase I in Alzheimer's disease.Pronuclear injection for the production of transgenic mice.Human but not rat amylin shares neurotoxic properties with Abeta42 in long-term hippocampal and cortical cultures.Glial cells under physiologic and pathologic conditions.Tau aggregation and its interplay with amyloid-β.Profiling murine tau with 0N, 1N and 2N isoform-specific antibodies in brain and peripheral organs reveals distinct subcellular localization, with the 1N isoform being enriched in the nucleus.What we can learn from animal models about cerebral multi-morbidity.
P50
Q26865759-EEBC34D2-F950-4752-99BE-342D0D6214FBQ26996848-7622199D-E6B0-45AA-AA82-1D7CC6DE0986Q27023429-2FDBB0C5-9123-44FF-913A-E371FF68E1F8Q28070250-FC22A8D8-79FF-4F73-AE75-3BF8C35442F6Q28119018-8763C2AC-E0B1-44AE-AEF3-633C593D0F23Q28119104-51FD014B-2523-4BDF-9426-D0F9621669C0Q28238356-346B6CB5-DEEB-4471-A155-AC4052525F12Q28478362-F7887096-52F7-45DE-8AC5-6232FF274CAEQ28506401-9991A94C-22A1-407F-9FF2-0393F5D2B466Q28507700-395F73E5-6BD8-4673-940B-D7E4E6245F5BQ28749702-7839373F-88B2-4767-9242-8C8CA7729E5DQ30473576-103271C7-E63F-4E09-BE94-981DD0BE3C00Q30578448-02354E5E-5D68-4A4A-A1F9-52B44C432F71Q30913572-C4EBF6A5-EEE8-48EE-BCAC-D4AB5D079962Q31005421-B55A0907-D5BB-42BF-91C6-75CC2C042B27Q31442641-8494CD9D-2BEF-40CF-8809-85C23C46B260Q33223501-21C9B0DC-8291-4755-BCA5-8F04974AC444Q33307478-C2E26680-63D6-4A6D-9624-6FD8ABFC0D3FQ33559266-4ED9675D-62FC-49E0-9F03-C03EC8F48A4EQ33603862-2E8F3F20-3B1D-4CAB-BCA8-7A87776EAB73Q33605734-C6EE347C-5289-4B55-A9FA-081C4A00DB56Q33713496-8B5D931B-A3FE-4051-A534-05ECC8FE73EBQ33798637-9D9369C2-D5B0-49D0-A552-4B400F831482Q33821316-945CB3B6-B9A1-4052-B6BE-909871E722C8Q33876147-F8826805-0694-4ADD-BEC9-E03D9E032672Q33987984-401C68AF-1FD5-47D3-ADDD-BF81F66D13BAQ34038251-E4371CAC-E67C-447D-8615-BA17A300F98CQ34043432-CB5922BB-D210-4811-846C-B24DA1376714Q34068459-B10625E5-B024-4901-B9C0-8E3BDA3B710BQ34100797-9F966A1C-EE02-421F-851D-112B080B222AQ34102829-BE447159-8F49-47EA-A576-D27355896065Q34148195-6761173E-91DD-401C-9F91-B5496E0E1649Q34256620-D9784D65-CD28-4EFA-B86B-84BF79842FD3Q34336935-6ED92935-F802-4D0E-839E-AE5EBBB681D9Q34633979-02987810-B259-40A5-834E-08E89156490DQ34779219-075CBD8B-53C7-4EFE-AA7B-63D0662A09EDQ34956464-CD86E70A-6F69-49B9-91E5-FAACBA406C26Q35008256-CFEE293E-4047-4520-955F-904E0066A20AQ35081058-2EBDCF6A-4886-4E9A-A7D1-5D20D1778AE0Q35215656-54874AA3-EAA1-4953-813B-9EAC099BE3DD
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jürgen Götz
@ast
Jürgen Götz
@en
Jürgen Götz
@es
Jürgen Götz
@nl
Jürgen Götz
@sl
type
label
Jürgen Götz
@ast
Jürgen Götz
@en
Jürgen Götz
@es
Jürgen Götz
@nl
Jürgen Götz
@sl
prefLabel
Jürgen Götz
@ast
Jürgen Götz
@en
Jürgen Götz
@es
Jürgen Götz
@nl
Jürgen Götz
@sl
P1053
C-2448-2014
P106
P1153
7006610653
P21
P31
P3829
P496
0000-0001-8501-7896